NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT03321643 2026-04-13
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04542824 2026-04-08
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-04-08
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT06508658 2026-04-08
EPCORE DLBCL-4
Genmab
Phase 3 Active not recruiting
NCT01679119 2026-04-07
INCA
University College, London
Phase 2 Completed
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05139017 2026-04-07
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT07451652 2026-04-01
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Recruiting
NCT06806033 2026-03-31
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT04384484 2026-03-24
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting